Progress in the Treatment of Cytomegalovirus Pneumonia
Authors: Ian Frank
Journal: Annals of Internal Medicine (1988)

Editorials15 November 1988Progress in the Treatment of Cytomegalovirus PneumoniaIan Frank, MD, Harvey M. Friedman, MDIan Frank, MDSearch for more papers by this author, Harvey M. Friedman, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-10-769 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe importance of cytomegalovirus infection in the immunocompromised host is well documented. Cytomegalovirus is the commonest form of life-threatening opportunistic viral infection in patients with the acquired immunodeficiency syndrome (AIDS) (1). The incidence of infection after renal transplantation, determined by rise in antibody titer or virus isolation, is 71%, averaged over 15 studies (2). Approximately 30% of heart transplant patients develop clinical cytomegalovirus disease, although subclinical infection can be documented in almost all patients (3). Cytomegalovirus is the commonest infectious cause of death after allogeneic bone marrow transplantation, primarily because of cytomegalovirus pneumonia (4).The clinical characteristics of cytomegalovirus pneumonia...References1. JacobsonMills MJ. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome. Ann Intern Med. 1988; 108:585-94. LinkGoogle Scholar2. Ho M. Cytomegalovirus: Biology and Infection. New York: Plenum Medical Book Co; 1982:172. CrossrefGoogle Scholar3. PollardArvinGambergRandGallagherMerigan AAPKJT. Specific cell mediated immunity and infections with herpes viruses in cardiac transplant recipients. Am J Med. 1982;73:679-87. CrossrefMedlineGoogle Scholar4. MeyersFlourneyThomas JNE. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153:478-88. CrossrefMedlineGoogle Scholar5. GrundyShanleyGriffiths JJP. Is cytomegalovirus interstitial pneumonitis in transplant patients an immunopathological condition? Lancet, 1987;2:996-9. CrossrefMedlineGoogle Scholar6. AppelbaumMeyersFefer FJA. Nonbacterial nonfungal pneumonia following marrow transplantation in 100 identical twins. Transplantation. 1982;33:265-68. CrossrefMedlineGoogle Scholar7. MillerFlynnMcCullough WPJ. Cytomegalovirus infection after bone marrow transplantation: an association with graft-vs-host disease. Blood. 1986:67:1162-7. CrossrefMedlineGoogle Scholar8. GrundyShanleyShearer JJG. Augmentation of graft-versus-host reaction by cytomegalovirus infection resulting in interstitial pneumonitis. Transplantation. 1985;39:548-53. CrossrefMedlineGoogle Scholar9. ShanleyPesantiNugent JEK. The pathogenesis of pneumonitis due to murine cytomegalovirus. J Infect Dis. 1982;146:388-96. CrossrefMedlineGoogle Scholar10. MatthewsBoehme TR. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988;10(Suppl 3):S490-4. CrossrefMedlineGoogle Scholar11. BuhlesMastreTinkerStrandKoretz WBAVS. Review of the treatment of 314 cases of life threatening or sight threatening cytomegalovirus infections. Rev Infect Dis. 1988;10(Suppl 3):S495-506. CrossrefMedlineGoogle Scholar12. SheppDandlikerde Miranda DPP. Activity of 9-[2-hydroxy-l-(hydroxymethyl)ethoxymethyl] guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med. 1985;103:368-73. LinkGoogle Scholar13. CrumpackerMarloweZhangAbramsWatkins CSJSP. Treatment of cytomegalovirus pneumonia. Rev Infect Dis. 1988;10(Suppl 3):S538-46. CrossrefMedlineGoogle Scholar14. MurrayFeltonGaray JCS. Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart Lung and Blood Institute Workshop. N Engl J Med. 1984;310:1682-8. CrossrefMedlineGoogle Scholar15. BlacklockGriffithsStirkPrentice HPPH. Specific hyperimmune globulin for cytomegalovirus pneumonitis. Lancet. 1985;1:152-3. CrossrefMedlineGoogle Scholar16. ReedBowdenDandlikerGleavesMeyers ERPCJ. Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J Infect Dis. 1987;156:641-5. CrossrefMedlineGoogle Scholar17. WilsonMedearisHansenRubin EDLR. 9-(1-3-dihydroxy-2-propoxymethyl)guanine prevents death but not immunity in murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. Antimicrob Agents Chemother. 1987;31:1017-20. CrossrefMedlineGoogle Scholar18. ReedBowdenDandlikerLillebyMeyers ERPKJ. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988;109:783-788. LinkGoogle Scholar19. EmanuelCunninghamJules-Elysee DIK. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988;109:777-782. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Pennsylvania Philadelphia, Pennsylvania Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByImplications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domainsValganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised hostCMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapyReactivation of Human Herpesviruses after Allogeneic Peripheral Blood Stem Cell Transplantation and Bone Marrow TransplantationCytomegalovirus pneumonia in a patient with breast cancer on chemotherapy: Case report and review of the literatureManagement of Cytomegalovirus Infection IN Solid-Organ Transplant RecipientsVIRUSES AND OTHER MISCELLANEOUS ORGANISMSPulmonary diseases in childhood AIDSCytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantationStrategies for the treatment and prevention of cytomegalovirus infectionsDiagnosis of fetal infection in the patient with an ultrasonographically detected abnormality but a negative clinical historyEarly Treatment with Ganciclovir to Prevent Cytomegalovirus Disease after Allogeneic Bone Marrow TransplantationCytomegalovirus myocarditis in transplanted heart verified by endomyocardial biopsyUpdate on Infections in the Immunocompromised Host9 Infections in the compromised childMedical Care of the HIV-Infected ChildPrevention of cytomegalovirus infection in the pediatric renal transplant recipientBilateral pseudothrombophlebitis.Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone.Cytomegalovirus Is Frequently Isolated in Bronchoalveolar Lavage Fluid of Bone Marrow Transplant Recipients without PneumoniaPetri Ruutu, MD, Tapani Ruutu, MD, Liisa Volin, MD, Pentti Tukiainen, MD, Pentti Ukkonen, MD, Tapani Hovi, MDInfection in Renal Transplantation: The First Six MonthsFailure of adjunctive cytomegalovirus intravenous immune globulin to improve efficacy of ganciclovir in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: a phase 1 studyCombined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c miceChanges in Therapeutic Proteins Caused by Preparation TechniquesJohn P. McCue, PhD, MPHGanciclovir and Immune Globulin in Cytomegalovirus PneumoniaDavid J. Morris, MRCPathLung and Heart-Lung Transplantation: A Review of Progress and Current Status based on the Registry of the International Society for Heart and Lung Transplantation 15 November 1988Volume 109, Issue 10Page: 769-771KeywordsAIDSBone marrow transplantationCardiovascular therapyCytomegalovirus infectionHeart diseasesInfectious diseasesOpportunistic infectionsPneumoniaRenal transplantation Issue Published: 15 November 1988 PDF DownloadLoading ...